PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.

Trial Details

NCT ID
NCT07607119
Phase
NA
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy)
  • PULSAR
Locations (sample)
  • Seoul, Select Province/State, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Age 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor b…
  • Unresectable, locally advanced extent at initial staging (Para-aortic lymph node \[PALN\] and Supraclavicular lymph node \[SCN\] metastases are all…
  • Has completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.
  • Presence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →